公开(公告)号：US20140072558A1

公开(公告)日：2014-03-13

申请号：US14009037

申请日：2012-04-03

Applicant: Young Woo Park ,  Ki Won Jo ,  Donghee Lee ,  Eun Kyung Lee ,  Seil Jang ,  Chan Woong Park ,  Dong-Jin Kim ,  Hye Nan Kim ,  Yun Jung Park ,  Jae Eun Park ,  Ji Hyun Park ,  Seok Ho Yoo ,  Myeoung Hee Jang

Inventor： Young Woo Park ,  Ki Won Jo ,  Donghee Lee ,  Eun Kyung Lee ,  Seil Jang ,  Chan Woong Park ,  Dong-Jin Kim ,  Hye Nan Kim ,  Yun Jung Park ,  Jae Eun Park ,  Ji Hyun Park ,  Seok Ho Yoo ,  Myeoung Hee Jang

IPC: A61K39/395 ,  G01N33/68 ,  A61K38/17

CPC classification number: A61K39/3955 ,  A61K38/1709 ,  A61K38/177 ,  A61K39/39558 ,  C07K14/705 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/622 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/485 ,  A61K2300/00

Abstract: The present invention relates to an activin receptor type II B (ACVR2B) inhibitor which comprises the delta-like 1 homolog (DLK1) extracellular water-soluble domain. More specifically, the present invention relates to an extracellular soluble domain of DLK1; fragments of the extracellular soluble domain of DLK1; mutants of the extracellular soluble domain of DLK1; a composition for suppressing ligand linkage with the ACVR2B receptor, which includes a fragment of the mutants as an active ingredient; and a pharmaceutical composition for prevention and treatment of diseases which comprises the same. The composition of the present invention competitively binds to the ACVR2B receptor and inhibits the binding of an ACVR2B ligand to the ACVR2B receptor, which inhibits protein signalling associated with such ligands, and will be useful for prevention and treatment of diseases associated therewith.

Abstract translation: 本发明涉及包含δ-样1同系物（DLK1）细胞外水溶性结构域的激活素受体IIB型（ACVR2B）抑制剂。 更具体地，本发明涉及DLK1的细胞外可溶性结构域; DLK1细胞外可溶性结构域的片段; DLK1细胞外可溶性结构域的突变体; 用于抑制与ACVR2B受体的配体键合的组合物，其包含突变体的片段作为活性成分; 以及用于预防和治疗包含该疾病的疾病的药物组合物。 本发明的组合物竞争性地结合ACVR2B受体并且抑制ACVR2B配体与ACVR2B受体的结合，所述ACVR2B受体抑制与这种配体相关的蛋白质信号，并且将可用于预防和治疗与之相关的疾病。

公开(公告)号：US20130323785A1

公开(公告)日：2013-12-05

申请号：US13883264

申请日：2011-11-04

Applicant: Jung Hoon Sohn ,  Jung Hoon Bae ,  Mi Jin Kim ,  Hyun Jin Kim ,  Soon Ho Park ,  Kwang Mook Lim

Inventor： Jung Hoon Sohn ,  Jung Hoon Bae ,  Mi Jin Kim ,  Hyun Jin Kim ,  Soon Ho Park ,  Kwang Mook Lim

IPC: C07K14/485 ,  C12R1/645

CPC classification number: C07K14/485 ,  C12N15/81 ,  C12R1/645

Abstract: The present invention relates to a method for producing hEGF (human epidermal growth factor) which has the same activity as the wild form, in high concentration and with a high degree of purity. More specifically, the invention relates to an hEGF expression vector comprising a nucleic acid sequence coding for the polypeptide of sequence number 14; a host cell in which the expression vector has been genetically transformed; and a method for producing hEGF, comprising a step in which the expression vector is created and is genetically transformed in yeast from which the KEX1 gene is lacking. Using the method of the present invention, it is possible to produce a large volume of human derived EGF which has the same size and activity as human derived EGF, and this EGF can be used in various ways such as in medicine and cosmetics.

Abstract translation: 本发明涉及以高浓度和高纯度生产具有与野生型相同的活性的hEGF（人表皮生长因子）的方法。 更具体地，本发明涉及包含编码序列号14的多肽的核酸序列的hEGF表达载体; 其中表达载体已被遗传转化的宿主细胞; 以及生产hEGF的方法，包括其中缺少表达载体并在KEX1基因缺失的酵母中遗传转化的步骤。 使用本发明的方法，可以生产与人源性EGF具有相同大小和活性的大量人源性EGF，并且该EGF可以以各种方式用于医药和化妆品中。

公开(公告)号：US20130296459A1

公开(公告)日：2013-11-07

申请号：US13884912

申请日：2011-11-10

Applicant: Moon-Hee Sung ,  Hiroshi Uyama ,  Iwamoto Mie ,  Jae-Chul Choi ,  Haryoung Poo ,  Chul Joong Kim

Inventor： Moon-Hee Sung ,  Hiroshi Uyama ,  Iwamoto Mie ,  Jae-Chul Choi ,  Haryoung Poo ,  Chul Joong Kim

IPC: A61L24/04 ,  C08K5/1545 ,  C08K5/053

CPC classification number: A61L24/046 ,  A61L15/58 ,  C08K5/053 ,  C08K5/1545 ,  C09J177/04 ,  C08L77/04

Abstract: The present invention provides a medical adhesive composition containing poly-gamma-glutamic acid or its salt; and sugar or sugar alcohol, which is edible, water-soluble, anionic and biodegradable. The invention also provides a thickener composition containing poly-gamma-glutamic acid, which can be used as a moisture-absorbing agent, a moisturizing agent and a raw material for cosmetic products.

Abstract translation: 本发明提供含有聚-γ-谷氨酸或其盐的医用粘合剂组合物; 和糖或糖醇，其是可食用的，水溶性的，阴离子的和可生物降解的。 本发明还提供含有聚-γ-谷氨酸的增稠剂组合物，其可以用作吸湿剂，保湿剂和化妆品的原料。

公开(公告)号：US08541005B2

公开(公告)日：2013-09-24

申请号：US12306903

申请日：2007-06-20

Applicant: Bong Hyun Chung ,  Jeong Min Lee ,  Sun-Ok Jung ,  Yongwon Jung

Inventor： Bong Hyun Chung ,  Jeong Min Lee ,  Sun-Ok Jung ,  Yongwon Jung

IPC: A61K39/09 ,  A61K39/085 ,  C12Q1/00

CPC classification number: C07K14/31 ,  C07K17/00 ,  C07K2319/00 ,  C07K2319/20 ,  G01N33/54366 ,  G01N33/54393 ,  G01N33/56938 ,  G01N33/6854 ,  G01N2333/31 ,  G01N2333/315

Abstract: The present invention relates to an N-terminal cysteine-tagged Streptococcal protein G variant. Since the variant binds in a directional manner to a surface of a biochip or a biosensor, the variant provides a biochip and a biosensor having an improved antibody-immobilizing capability, compared with an untagged protein G variant.

Abstract translation: 本发明涉及N-末端半胱氨酸标记的链球菌蛋白G变体。 由于变体以定向方式结合生物芯片或生物传感器的表面，与未标记的蛋白G变体相比，该变体提供具有改进的抗体固定能力的生物芯片和生物传感器。

公开(公告)号：US20130245068A1

公开(公告)日：2013-09-19

申请号：US13891837

申请日：2013-05-10

Applicant: Byoung Mog KWON ,  Dong Cho HAN ,  Dae Seop SHIN ,  Young Min HAN

Inventor： Byoung Mog KWON ,  Dong Cho HAN ,  Dae Seop SHIN ,  Young Min HAN

IPC: A61K31/445 ,  A61K45/06 ,  A61K31/4453

CPC classification number: A61K31/445 ,  A61K31/44 ,  A61K31/4453 ,  A61K31/4462 ,  A61K45/06

Abstract: The present invention relates to a novel pharmaceutical composition of benproperine derivatives for preventing and treating angiogenesis-related diseases. The benproperine derivatives and pharmaceutically acceptable salts thereof according to the present invention inhibit cancer cell migration and the angiogenesis of vascular endothelial cells, and therefore can be effectively used not only as an anticancer agent, but also as an agent for preventing and treating diseases caused by abnormal angiogenesis, such as diabetic retinopathy and corneal transplant rejection.

Abstract translation: 本发明涉及一种用于预防和治疗血管发生相关疾病的苯丙孕酮衍生物的新型药物组合物。 本发明的benproperine衍生物及其药学上可接受的盐抑制癌细胞迁移和血管内皮细胞的血管生成，因此不仅可以有效地用作抗癌剂，而且可以作为预防和治疗由 异常血管发生，如糖尿病视网膜病变和角膜移植排斥。

公开(公告)号：US20130237542A1

公开(公告)日：2013-09-12

申请号：US13880642

申请日：2011-10-17

Applicant: Kyeong Lee ,  Mi Sun Won ,  Hwan Mook Kim ,  Song Kyu Park ,  Kiho Lee ,  Ki Hoon Lee ,  Chang Woo Lee ,  Jung Joon Lee ,  Kyung Sook Chung ,  Bo Kyung Kim ,  Yinglan Jin ,  Seung-hee Lee

Inventor： Kyeong Lee ,  Mi Sun Won ,  Hwan Mook Kim ,  Song Kyu Park ,  Kiho Lee ,  Ki Hoon Lee ,  Chang Woo Lee ,  Jung Joon Lee ,  Kyung Sook Chung ,  Bo Kyung Kim ,  Yinglan Jin ,  Seung-hee Lee

IPC: C07C235/28 ,  C07D295/088 ,  C07C311/16

CPC classification number: A61K31/5375 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/14 ,  A61K9/20 ,  A61K9/48 ,  A61K31/167 ,  A61K31/196 ,  A61K31/24 ,  A61K31/34 ,  A61K31/40 ,  A61K31/417 ,  A61K31/4409 ,  C07C233/07 ,  C07C235/28 ,  C07C311/16 ,  C07C311/46 ,  C07C317/40 ,  C07C2603/74 ,  C07D295/088

Abstract: The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.

Abstract translation: 本发明涉及抑制HF-1活性的化合物，其制备方法以及含有该化合物作为活性成分的药物组合物。 本发明的化合物通过非选择性细胞毒性表现出抗癌活性，但通过抑制HIF-1的活性，该转录因子在癌细胞生长和转移中起重要作用。 因此，根据本发明的化合物或其药学上可接受的盐抑制HIF-1活性，因此可以用作结肠癌，肝癌，胃癌和乳腺癌等实体瘤的治疗剂。 此外，根据本发明的化合物或其药学上可接受的盐可以用作用于糖尿病性视网膜病变或关节炎的治疗剂的活性成分，当HIF-1的缺氧诱导的VEGF表达增加时，可能变差。

公开(公告)号：US20130224856A1

公开(公告)日：2013-08-29

申请号：US13669896

申请日：2012-11-06

Applicant: Korea Research Institute of Bioscience and Biotec

Inventor： Yee Sook Cho ,  Mi Young Son ,  Hyun Jin Kim

IPC: C12N5/0735

CPC classification number: C12N5/0606 ,  C12M23/12 ,  C12M25/06 ,  C12M45/02 ,  C12M45/09 ,  C12N5/0603 ,  C12N2509/10

Abstract: The present invention relates to a large-scale propagation and maintenance method of embryoid bodies generated from stem cells. More particularly, the present invention relates to a large-scale propagation and maintenance method of embryoid bodies retaining their intrinsic characteristics for a long period of time, comprising the step of continuously subculturing embryoid bodies that are primarily produced from embryonic stem cells or from induced pluripotent stem cells. According to the method of the present invention, after preparation of embryoid bodies from a limited number of stem cells, large-scale production and maintenance of embryoid bodies can be realized by a simple mechanical subculturing method without the continuous supply of stem cells.

Abstract translation: 本发明涉及从干细胞产生的胚状体的大规模繁殖和维持方法。 更具体地说，本发明涉及长期保持其固有特征的胚状体的大规模繁殖和维持方法，包括连续传代培养主要由胚胎干细胞或诱导多能的胚状体的步骤 干细胞。 根据本发明的方法，在从有限数量的干细胞制备胚状体后，通过简单的机械传代培养方法可以实现胚状体的大规模生产和维持，而不需要连续供应干细胞。

公开(公告)号：US20130190200A1

公开(公告)日：2013-07-25

申请号：US13704423

申请日：2010-12-08

Applicant: Jin Cheon Kim ,  Yong Sung Kim ,  Seon Young Kim ,  Dong Hyung Cho

Inventor： Jin Cheon Kim ,  Yong Sung Kim ,  Seon Young Kim ,  Dong Hyung Cho

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The present invention relates to a single nucleotide polymorphism (SNP) for predicting the sensitivity to an anticancer targeted therapeutic formulation, a polynucleotide containing the same, and a method for predicting the sensitivity to an anticancer targeted therapeutic formulation. According to the present invention, it is possible to predict the sensitivity of each individual to a certain anticancer targeted therapeutic formulation, using a small amount of a sample taken from a patient and thus to select a most suitable targeted therapeutic formulation over the entire duration of treatment for the patient.

Abstract translation: 本发明涉及用于预测对抗癌靶向治疗制剂的敏感性的单核苷酸多态性（SNP），含有该制剂的多核苷酸，以及预测对抗癌靶向治疗剂型的敏感性的方法。 根据本发明，可以使用少量来自患者的样品来预测每个个体对某种抗癌靶向治疗剂型的敏感性，从而在整个持续时间内选择最合适的靶向治疗制剂 治疗病人。

公开(公告)号：US20130149374A1

公开(公告)日：2013-06-13

申请号：US13697705

申请日：2010-11-12

Applicant: Myung Kyu Lee ,  Abbas Mokhtarieh Amir ,  Bong Hyun Chung ,  Jong Min Choi

Inventor： Myung Kyu Lee ,  Abbas Mokhtarieh Amir ,  Bong Hyun Chung ,  Jong Min Choi

IPC: A61K9/127 ,  A61K31/713

CPC classification number: A61K9/1272 ,  A61K9/1271 ,  A61K9/1277 ,  A61K31/122 ,  A61K31/70 ,  A61K31/713

Abstract: The present invention relates to asymmetric liposomes for high encapsulation efficiency of nucleic acids and hydrophilic anionic compounds, and to a method for preparing same, and specifically, to asymmetric liposomes consisting of a cationic lipid having a small head group as an internal lipid and a neutral or PEGylated lipid having a big head group as an external lipid, wherein nucleic acids and/or anionic compounds are encapsulated in the internal lipid. According to the present invention, asymmetric liposomes, in which nucleic acids and hydrophilic anionic compounds are encapsulated with high efficiency, may be prepared, and thus the same may be used for various purposes, such as gene therapy, and the delivery of hydrophilic anionic drugs which are difficult to prepare as prodrugs, and drug delivery, imaging, etc. can be carried out by encapsulating a fluorescent contrast agent in the liposome.

Abstract translation: 本发明涉及用于核酸和亲水性阴离子化合物的高包封效率的不对称脂质体及其制备方法，具体涉及由具有小头基团作为内部脂质和中性的阳离子脂质组成的不对称脂质体 或具有大头基的聚乙二醇化脂质作为外部脂质，其中核酸和/或阴离子化合物包封在内部脂质中。 根据本发明，可以制备其中核酸和亲水性阴离子化合物以高效率包封的不对称脂质体，因此可以用于各种目的，例如基因治疗和递送亲水性阴离子药物 其难以作为前药制备，并且药物递送，成像等可以通过将荧光对比剂包封在脂质体中来进行。

公开(公告)号：US20130053443A1

公开(公告)日：2013-02-28

申请号：US13696060

申请日：2011-05-03

Applicant: Cheol Goo Hur ,  Duck Sun Park ,  Hyo Nam Park ,  Jong Soon Lee ,  Hwang Yong Lee

Inventor： Cheol Goo Hur ,  Duck Sun Park ,  Hyo Nam Park ,  Jong Soon Lee ,  Hwang Yong Lee

IPC: C11B1/10 ,  C07C57/12 ,  A61P3/06 ,  A61K31/202

CPC classification number: C11B1/104 ,  A23L33/12 ,  A23V2002/00 ,  A61K9/2018 ,  A61K9/2059 ,  A61K36/185 ,  A61K36/535 ,  A61K2236/37 ,  C11B1/04 ,  Y02P20/544 ,  A23V2200/3262

Abstract: The present invention relates to a method for preparing an extract containing omega fatty acids from a plant containing omega fatty acids, including the following steps: drying the plant containing omega fatty acids to prepare a powder; and extracting omega fatty acids from the prepared plant powder by using supercritical carbon dioxide as a solvent at an optimum temperature and pressure, a dietary supplement and a cholesterol-lowering pharmaceutical composition containing plant-derived omega fatty acids extracted by the method, and omega fatty acids-containing plant extract containing a predetermined or greater amount of omega-3 fatty acids.

Abstract translation: 本发明涉及从含有ω脂肪酸的植物制备含有ω脂肪酸的提取物的方法，包括以下步骤：干燥含有ω脂肪酸的植物以制备粉末; 并通过在最佳温度和压力下使用超临界二氧化碳作为溶剂从制备的植物粉末中提取ω-脂肪酸，膳食补充剂和含有通过该方法提取的植物衍生的ω-脂肪酸的降胆固醇药物组合物和ω-脂肪酸 含有预定量或更多量的ω-3脂肪酸的含酸植物提取物。